tetano
Editor, Senior Moderator
Expert Rev Vaccines
. 2021 Jan 12.
doi: 10.1080/14760584.2021.1875823. Online ahead of print.
Quadrivalent Influenza Vaccine (Sinovac Biotech) for seasonal influenza prophylaxis
Yan-Yang Tao[SUP] 1 [/SUP], Jing-Xin Li[SUP] 2 [/SUP], Yue-Mei Hu[SUP] 2 [/SUP], Yuan-Sheng Hu[SUP] 3 [/SUP], Gang Zeng[SUP] 3 [/SUP], Feng-Cai Zhu[SUP] 1 2 4 [/SUP]
Affiliations
Abstract
Introduction: Quadrivalent Influenza Vaccine (Sinovac Biotech) is a quadrivalent split-virion inactivated influenza vaccine approved in China in June 2020 for individuals ≥3 years of age. It contains 15 ?g hemagglutinin per strain including A/H1N1, A/H3N2, B/Victoria, and B/Yamagata, which could potentially improve protection against influenza B viruses.
Areas covered: In this review, we summarize the development of quadrivalent influenza vaccines in China and foreign countries, and assess the immunogenicity and safety from the phase I and III clinical trials of Quadrivalent Influenza Vaccine in individuals ≥3 years of age. We also discuss the potential application of Quadrivalent Influenza Vaccine in young children 6-35 months of age according to the results of the phase III trial.
Expert commentary: The immunogenicity and safety profiles of Quadrivalent Influenza Vaccine containing two A and two B strains were comparable to the trivalent vaccines for the shared strains. The addition of a second B strain to the trivalent vaccine could induce superior immune responses for the alternate B strain. Since the two B strains co-circulated worldwide, the introduction of quadrivalent influenza vaccines has been expected to be a cost-effective strategy.
Keywords: Immunogenicity; Inactivated influenza vaccine; Quadrivalent influenza vaccine; Safety; Seasonal influenza.
. 2021 Jan 12.
doi: 10.1080/14760584.2021.1875823. Online ahead of print.
Quadrivalent Influenza Vaccine (Sinovac Biotech) for seasonal influenza prophylaxis
Yan-Yang Tao[SUP] 1 [/SUP], Jing-Xin Li[SUP] 2 [/SUP], Yue-Mei Hu[SUP] 2 [/SUP], Yuan-Sheng Hu[SUP] 3 [/SUP], Gang Zeng[SUP] 3 [/SUP], Feng-Cai Zhu[SUP] 1 2 4 [/SUP]
Affiliations
- PMID: 33434084
- DOI: 10.1080/14760584.2021.1875823
Abstract
Introduction: Quadrivalent Influenza Vaccine (Sinovac Biotech) is a quadrivalent split-virion inactivated influenza vaccine approved in China in June 2020 for individuals ≥3 years of age. It contains 15 ?g hemagglutinin per strain including A/H1N1, A/H3N2, B/Victoria, and B/Yamagata, which could potentially improve protection against influenza B viruses.
Areas covered: In this review, we summarize the development of quadrivalent influenza vaccines in China and foreign countries, and assess the immunogenicity and safety from the phase I and III clinical trials of Quadrivalent Influenza Vaccine in individuals ≥3 years of age. We also discuss the potential application of Quadrivalent Influenza Vaccine in young children 6-35 months of age according to the results of the phase III trial.
Expert commentary: The immunogenicity and safety profiles of Quadrivalent Influenza Vaccine containing two A and two B strains were comparable to the trivalent vaccines for the shared strains. The addition of a second B strain to the trivalent vaccine could induce superior immune responses for the alternate B strain. Since the two B strains co-circulated worldwide, the introduction of quadrivalent influenza vaccines has been expected to be a cost-effective strategy.
Keywords: Immunogenicity; Inactivated influenza vaccine; Quadrivalent influenza vaccine; Safety; Seasonal influenza.